Nexus is a next-generation integrated ultrasonic surgical platform that combines all the features of Misonix’s existing solutions, including BoneScalpel, SonicOne and Sonastar, into a single fully integrated platform that will also serve to power future solutions. The Nexus platform is driven by a new proprietary digital algorithm that results in more power, efficiency and control. Nexus uniquely incorporates RF capabilities, allowing for use in general surgery procedures. The device also incorporates Smart Technology that allows for easier setup and use.
Physicians will be able to utilize Nexus’ increased power to improve tissue resection rates, in concert with its proprietary digital algorithm to perform more efficient bone removal procedures. In addition, Nexus’ ease of use will enable physicians to fully leverage Nexus’ impressive capabilities via its digital touchscreen display and smart system setup.
Stavros Vizirgianakis, President and Chief Executive Officer of Misonix, commented, “We are very pleased to have achieved this critical approval, marking a significant milestone for Misonix and the culmination of years of hard work.” Nexus is a powerful, highly integrated and easy-to-use system that will benefit both healthcare providers and patients by incorporating the latest advances in ultrasonic technology allowing for increased efficiency and efficacy, and thus improved outcomes. It is truly a transformational product.
“The overwhelmingly positive feedback we have received from the surgeon community since first unveiling Nexus reinforces our confidence in its potential to serve as a significant growth engine for Misonix. Nexus is a key component of our strategy to increase our presence in the neuro, spine, ortho, wound and general surgery markets. Nexus provides us with a unique opportunity to leverage our robust consignment business model, further drive the sale of consumables competitively, and extend our ability to cross-sell into multiple physician specialties. The commercialization of Nexus will expand the utilization of ultrasonic surgical applications as we continue to strategically invest in our products to become the standard of care in operating rooms and hospital outpatient departments.”
Omnica had the honor of developing the last pH meter product family before Dr. Beckman passed away in 2004. We worked with the client’s Industrial Design to produce a family eighteen meter variations based on a single PCB.
The handheld versions passed the requirement of IPX7 (water ingress protection at a submersion level one meter, even though it floats).
SSO2 THERAPY FOR AMI
Current standard of care for the most severe heart attacks involves mechanically opening the blocked artery using percutaneous coronary intervention (PCI), otherwise known as angioplasty and stenting. While PCI has reduced early mortality post-heart attack over the past 25 years, significant myocardial tissue (heart muscle) death and sizable scarring may be present even after the left anterior descending (LAD) artery has been stented. This myocardial damage is linked to increased risk of heart failure and long-term mortality2.
SSO2Therapy is a novel treatment that complements PCI and is designed to minimize myocardial damage caused by acute myocardial infarction in qualifying patients suffering a LAD ST-elevation myocardial infarction (STEMI) event who are treated with primary PCI within 6 hours of symptom onset. SSO2 Therapy delivers superoxygenated arterial blood directly to at-risk myocardial tissue and is performed in the cardiac catheterization laboratory immediately after PCI is completed.
Thermastar™ for Volcano Therapeutics – Intravascular thermography device for research. This system measures minute interior artery temperature changes and identifies areas where arterial plaque may form. We proved feasibility of the client’s proprietary arterial catheter, and based on that technology we developed a complete diagnostic system which could be used in a clinical setting. We designed a custom keyboard, the PC cart housing, a handheld controller, and the video-based GUI for the operating software. Our in-house team managed the manufacture of the rotomolded parts, controller and keyboards. We prototyped and assembled 10 fully operational units.
Omnica partnered with bioMerieux’s marketing and engineering teams in developing this entry to their Lab of the Future with contributions to basic functionality, user experience, Industrial Design and prototyping. Their introduction announcement follows:
Get ready for a new dimension in blood culture detection: the BACT/ALERT® VIRTUO® is seamlessly efficient blood culture technology in one automated system.
- Motion-activated “Set and Forget” loading
- Advanced robotics provides hands free bottle loading and unloading
- Flexible and scalable instrumentation adapts to any size laboratory
- VIRTUO® helps you redesign your workflow by reducing hands on time and increasing efficiency
BACT/ALERT® VIRTUO® ushers in a new dimension of blood culture detection. Almost endlessly versatile it fits into any size lab, even outside the routine microbiology lab. The latest example of ingenuity in automation, VIRTUO™ reduces hands-on time for increased lab efficiency. These benefits can be further boosted through highly sophisticated MYLA® software that puts relevant information from multiple instruments and your LIS at your fingertips, when and where you need it. In these ways and more, BACT/ALERT® VIRTUO® seamlessly integrates your blood culture workflow to provide efficient and actionable results to help you achieve better patient outcomes.
The innovative KickTrak by babykick is a non-invasive, handheld device that tracks a baby’s movement patterns, counts down pregnancy progress and reliably tracks the time between contractions to better estimate when labor will begin. KickTrak provides peace of mind to expecting mothers as fetal movement is an important indicator of babies’ health. Pregnant women use kickTrak beginning at 24-28 weeks to record their baby’s movements with the touch of a button.
Minimed Paradigm® for MiniMed (now Medtronic) – This percutaneous insulin infusion pump is the basis for a family of wearable and water-resistant insulin pumps. It supports three basal programs and a bolus delivery option. We developed a custom, non Luer lock connector to allow for the water-resistant design. It uses a proprietary stepper motor with a captive lead screw and is powered by an easily replaceable AAA battery. We performed project management and coordination with the client’s engineering team, industrial design, graphic interface, enclosure design, electronics packaging and others. We also fabricated test fixtures for life testing motors and force sensors, and designed the occlusion sensor and thin film force sensor transducer design. We coordinated tooling, drop, immersion, and acoustic testing, and documentation transfer to production.
A novel platform of magnetically adjustable implant systems based on its MAGnetic External Control technology. Ellipse’s novel and proprietary implants are adjustable at the time of implantation and are distracted non−invasively over the course of treatment to accommodate the changing clinical needs of patients as they heal, grow or age. Ellipse’s technology enables physicians to customize therapy for patients in a non-invasive manner, reducing the need for further repeat surgical procedures, and providing meaningful improvements in patient clinical outcomes and quality of life while generating cost savings to the healthcare system.
The NeuroThera System, De Taboada said, consists of a fiber optic cable, a handpiece, a cap that guides the laser energy to treatment locations on the scalp, accessories and a cart for portability.
When the system establishes contact with the patient’s completely shaved head, detectors in the handpiece trigger it to emit a specific wavelength of near-IR energy. “A total treatment regimen consists of treating 20 locations on the head for two minutes at each location for a total of 40 minutes of nominal treatment time,” De Taboada said.
The mitochondrial photoreceptor cytochrome C oxidase absorbs near-IR and drives adenosine triphosphate (ATP) formation by oxidative phosphorylation, he explained. The hypothesis goes that improved energy metabolism leads to mitigation of cell death in the stroke-affected tissue and to the enhancement of neuro-recovery mechanisms.
The improved neurometabolism could be beneficial not only in stroke treatment, but also in treating traumatic brain injury, and Parkinson’s and Alzheimer’s diseases, he said.
This portable instrument treats with NovaVision’s VRT therapy technology to provide improvement in the range or sensitivity of the patient’s field of vision. Omnica developed this home use transforming device to accommodate a full range of patient percentiles and provide a convenient way to go mobile with your therapy. NovaVision’s VRT uses repetitive light stimulation to activate impaired visual functions in areas of partial injury (“transition zones”), strengthening the residual vision and neuronal networks. The concept of repetitive stimulation has proven effective in the recovery of other functions such as movements of lower limbs after stroke.